Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Isosorbide Mononitrate Tablet Market CAGR Analysis And Future Market Development
Fueled by an increasing incidence of coronary artery disease, the prolonged therapeutic application of nitrates for managing angina, a growing elderly demographic, the accessibility of affordable generic medications, and the broadening network of hospital and retail pharmacy facilities, the market for isosorbide mononitrate tablets has experienced robust expansion. This market is projected to expand from its current valuation of $1.2 billion in 2025 to $1.26 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.3% during this period.
The market for isosorbide mononitrate tablets is poised for substantial expansion in the upcoming years, projected to reach a value of $1.55 billion by 2030, driven by a compound annual growth rate of 5.3%. This anticipated growth throughout the forecast period is underpinned by several key factors, including the escalating prevalence of chronic cardiovascular diseases, a growing consumer preference for extended-release tablet options, the increasing utilization of online pharmacies, enhanced diagnostic capabilities for angina and heart failure, and the broadening availability of cardiovascular treatments in developing economies. Furthermore, significant trends expected to shape this market include the development of long-acting therapies for cardiovascular maintenance, a heightened demand for extended-release drug formulations, a greater uptake of generic nitrate medications, enhanced patient compliance facilitated by once-daily dosing regimens, and an expanded reach through both online and traditional retail pharmacy channels.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24268&type=smp
Isosorbide Mononitrate Tablet Market Demand Drivers Creating New Revenue Opportunities
The increasing incidence of heart and blood vessel conditions is anticipated to stimulate the expansion of the isosorbide mononitrate tablet sector moving ahead. These circulatory system ailments encompass issues like narrowed arteries, weakened cardiac function, and elevated blood pressure. Such a surge in cardiovascular ailments is largely linked to dietary habits characterized by excessive saturated fats, trans fats, sodium, and added sugars, contributing to weight gain, hypertension, and high cholesterol. Isosorbide mononitrate tablets aid in managing these conditions by dilating and relaxing the vessels, subsequently enhancing blood flow and decreasing the heart’s effort, thereby easing angina, reducing blood pressure, and boosting oxygen supply to the cardiac muscle. For context, global mortality from cardiovascular diseases reached 19.2 million in 2023, as noted in a September 2025 report from the American College of Cardiology, a prominent US cardiology organization. Consequently, the growing burden of cardiovascular diseases is a key factor propelling the isosorbide mononitrate tablet market.
The proliferation of e-pharmacies is projected to be a significant catalyst for the expansion of the isosorbide mononitrate tablet market in the foreseeable future. E-pharmacies represent digital avenues where individuals can procure medications, both prescription and non-prescription, via the internet. This upward trend in online drugstores is predominantly driven by consumers’ escalating desire for ease of access, lower costs, and greater availability of medicines and health-related goods, eliminating the necessity of visiting brick-and-mortar establishments. These digital platforms enhance the accessibility of isosorbide mononitrate tablets through services like direct-to-home delivery, competitive pricing strategies, and improved stock levels, particularly beneficial for individuals managing long-term health issues. For illustration, data from May 2024, shared by the World Health Organization, indicated that digital requests for prescription renewals via the UK’s NHS App saw a substantial rise of over 45% in 2023, averaging 3.1 million requests monthly. Accordingly, the increasing presence and adoption of e-pharmacies are fostering growth in the isosorbide mononitrate tablet market.
Isosorbide Mononitrate Tablet Market Segmentation: How Is The Market Structured Across Key Categories?
The isosorbide mononitrate tablet market covered in this report is segmented –
1) By Dosage Form: Immediate-Release Tablets, Extended-Release Tablets
2) By Indication Type: Angina Pectoris, Coronary Artery Disease (CAD)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Immediate-Release Tablets: Low-Dose, Single Strength Tablets
2) By Extended-Release Tablets: Moderate-Dose, High-Dose, Once-Daily Formulation, Twice-Daily Formulation
Isosorbide Mononitrate Tablet Market Trends Driving Strategic Industry Expansion
Pharmaceutical giants in the isosorbide mononitrate tablet arena are concentrating their efforts on pioneering novel offerings, like extended-release (ER) versions, aimed at improving how patients adhere to their treatment, ensuring enduring medicinal benefits, and refining therapeutic results for ailments such as angina pectoris. This sophisticated extended-release delivery mechanism facilitates a slow, sustained dispersal of the drug over a prolonged duration, thereby decreasing the need for frequent administration and preserving stable concentrations within the bloodstream. Illustrating this trend, Zydus Lifesciences Limited, a pharmaceutical producer headquartered in India, secured authorization in February 2024 from the U.S. Food and Drug Administration (USFDA) to commence the production and sale of isosorbide mononitrate extended-release tablets USP in 30 mg, 60 mg, and 120 mg dosages. These tablets serve the crucial purpose of averting chest pain episodes, commonly known as angina, in individuals diagnosed with coronary artery disease, and are bioequivalent to the benchmark Imdur extended-release tablets.
Isosorbide Mononitrate Tablet Market Competitive Landscape And Leading Companies
Major companies operating in the isosorbide mononitrate tablet market are Pfizer Inc., Merck & Co., Inc., AstraZeneca plc, Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Zydus Lifesciences Limited, Torrent Pharmaceuticals Ltd., Micro Labs Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd., Mylan N.V., Hikma Pharmaceuticals PLC, Sandoz International GmbH, Qilu Pharmaceutical Co., Ltd., Lunan Pharmaceutical Group, Shandong Keyuan Pharmaceutical Co., Ltd.
Access The Complete Isosorbide Mononitrate Tablet Market Report:
https://www.thebusinessresearchcompany.com/report/isosorbide-mononitrate-tablet-global-market-report
Isosorbide Mononitrate Tablet Market Largest Region: Which Geography Holds The Highest Market Share?
North Americawas the largest region in the isosorbide mononitrate tablet market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the isosorbide mononitrate tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
